Categories Consumer, Earnings, Retail

NewAge Beverages misses Q4 revenue expectations

NewAge Beverages Corporation (NASDAQ: NBEV) missed revenue estimates for the fourth quarter of 2019 while losses were wider-than-expected. Shares were down 6.8% in premarket hours on Monday.  

Total revenues of $59.2 million were up 323% from the same period last year but fell short of forecasts of $66.2 million.  

Net loss widened to $65.9 million, or $0.83 per share, from a net loss of $2.6 million, or $0.04 per share, in the prior-year period, due to a $44.9 million impairment charge. Analysts had projected a loss of $0.08 per share.

Adjusted EBITDA was a loss of $17.4 million compared to an adjusted EBITDA loss of $8.7 million in the prior year period.

Also see: NewAge Beverages Q4 2019 Earnings Preview

CEO Brent Willis, said, “In 2019 we increased our scale five times, evolving from a $50 million company to one with net revenue above $250 million. Whilst doing so, we gained access to a range of new channels and opportunities across our infrastructure that now spans 60 countries worldwide. We also added global iconic brands like Nestea, Volvic, Illy, and Evian to our portfolio, strengthened our platform worldwide and made important investments in our leadership team.” 

Gross profit increased to $32.2 million from $3.2 million in the year-ago quarter while gross margin rose to 54.3% from 23% last year, helped by favorable product and channel mix.   

During the quarter, the company rolled out its ‘NHANCED hemp topical products in Australia and New Zealand. NewAge plans to launch these products in Korea, Taiwan and 32 markets in Europe going forward.

Last month, NewAge launched its CBD beverage Noni+CBD in Japan. The product was the first to gain approval from Japanese health authorities, thus giving the company a first mover advantage in this globally important market.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top